Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes.

Thankamony A, Tossavainen PH, Sleigh A, Acerini C, Elleri D, Dalton RN, Jackson NC, Umpleby AM, Williams RM, Dunger DB

The Journal of clinical endocrinology and metabolism11 Dec 2013Cited by 22 (Europe PMC)

PMID24423298DOI10.1210/jc.2013-3264PepBankPUB-24423298

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, pegvisomant lowered IGF-I compared with placebo (P < .001).
In plain wordsIn young adults with type 1 diabetes, pegvisomant lowered IGF-I compared with placebo.
Peptide
Pegvisomant
Outcome
DecreaseIGF-I
Study
n = 10
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, pegvisomant treatment resulted in lower IGF-I levels (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329801
02HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, pegvisomant reduced overnight insulin requirements for euglycemia compared with placebo (P = .019).
In plain wordsIn young adults with type 1 diabetes, pegvisomant reduced overnight insulin requirements compared with placebo.
Peptide
Pegvisomant
Outcome
DecreaseOvernight insulin requirements
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
During the overnight steady state, insulin requirements for euglycemia (P = .019), insulin levels (P = .008), and glucose production rates (Ra) (P = .033) were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329802
03HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, pegvisomant reduced overnight insulin levels compared with placebo (P = .008).
In plain wordsIn young adults with type 1 diabetes, pegvisomant reduced overnight insulin levels compared with placebo.
Peptide
Pegvisomant
Outcome
DecreaseOvernight insulin levels
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
During the overnight steady state, insulin requirements for euglycemia (P = .019), insulin levels (P = .008), and glucose production rates (Ra) (P = .033) were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329803
04HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, pegvisomant reduced overnight glucose production compared with placebo (P = .033).
In plain wordsIn young adults with type 1 diabetes, pegvisomant reduced overnight glucose production compared with placebo.
Peptide
Pegvisomant
Outcome
DecreaseOvernight glucose production
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
During the overnight steady state, insulin requirements for euglycemia (P = .019), insulin levels (P = .008), and glucose production rates (Ra) (P = .033) were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329804
05HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, pegvisomant increased clamp glucose infusion rates compared with placebo (P = .031).
In plain wordsIn young adults with type 1 diabetes, pegvisomant increased clamp glucose infusion rates compared with placebo.
Peptide
Pegvisomant
Outcome
IncreaseClamp glucose infusion rate
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
During the clamp study, glucose infusion rates (P = .031) increased and glucose Ra (P = .015) decreased whereas glucose disposal rates were unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329805
06HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, pegvisomant reduced clamp glucose production compared with placebo (P = .015).
In plain wordsIn young adults with type 1 diabetes, pegvisomant reduced clamp glucose production compared with placebo.
Peptide
Pegvisomant
Outcome
DecreaseClamp glucose production
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
During the clamp study, glucose infusion rates (P = .031) increased and glucose Ra (P = .015) decreased whereas glucose disposal rates were unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329806
07HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, glucose disposal rates were unchanged with pegvisomant compared with placebo.
In plain wordsIn young adults with type 1 diabetes, pegvisomant did not change glucose disposal compared with placebo.
Peptide
Pegvisomant
Outcome
No significant changeClamp glucose disposal
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
During the clamp study, glucose infusion rates (P = .031) increased and glucose Ra (P = .015) decreased whereas glucose disposal rates were unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329807
08HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, steady-state free fatty acid levels were similar with pegvisomant and placebo.
In plain wordsIn young adults with type 1 diabetes, steady-state free fatty acid levels were similar with pegvisomant and placebo.
Peptide
Pegvisomant
Outcome
No significant changeSteady-state free fatty acids
Study
n = 10
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
Free fatty acid levels were similar during the steady state but were lower during the clamp (P = .040) after pegvisomant.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329808
09HumanRandomized controlled trialEfficacy outcome
In young adults with type 1 diabetes, pegvisomant lowered clamp free fatty acid levels compared with placebo (P = .040).
In plain wordsIn young adults with type 1 diabetes, pegvisomant lowered clamp free fatty acid levels compared with placebo.
Peptide
Pegvisomant
Outcome
DecreaseClamp free fatty acids
Study
n = 10
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
Free fatty acid levels were similar during the steady state but were lower during the clamp (P = .040) after pegvisomant.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329809
10HumanNon-randomized trialEfficacy outcome
In young adults with type 1 diabetes, soleus intramyocellular lipid decreased after pegvisomant treatment (P = .024).
In plain wordsIn young adults with type 1 diabetes, soleus muscle lipid decreased after pegvisomant compared with before treatment.
Peptide
Pegvisomant
Outcome
DecreaseSoleus intramyocellular lipid
Study
n = 10
Comparator
Before treatment
Outcome group
Lipids · Musculoskeletal
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
Soleus muscle IMCL decreased after treatment (P = .024); however, no change in tibialis anterior muscle was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329810
11HumanNon-randomized trialEfficacy outcome
In young adults with type 1 diabetes, tibialis anterior intramyocellular lipid did not change after pegvisomant treatment.
In plain wordsIn young adults with type 1 diabetes, tibialis anterior muscle lipid did not change after pegvisomant compared with before treatment.
Peptide
Pegvisomant
Outcome
No significant changeTibialis anterior intramyocellular lipid
Study
n = 10
Comparator
Before treatment
Outcome group
Lipids · Musculoskeletal
Studied dose
10 mg · 4 weeksAs given in this study (human).
Source sentences
Summary
Soleus muscle IMCL decreased after treatment (P = .024); however, no change in tibialis anterior muscle was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, placebo-controlled, crossover study, 10 young adults with T1D were evaluated at baseline and after 4 weeks of treatment with either 10 mg of pegvisomant or placebo.
Report a problemFND-2442329811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.